Compliance Risk and Diligence
Complying with anti-money laundering and anti-bribery and corruption regulations.Compliance Risk and Diligence
John Arvanitis is a managing director in the Compliance Risk and Diligence practice of Kroll based in the Boston Office. John advises clients worldwide on anti-money laundering matters and other aspects of compliance programs, bringing impactful and valuable insight to their challenges via his extensive international and domestic financial investigative experience. He has significant experience across a broad range of compliance-related programs, including anti-money laundering, know your customer, global AML processes, and program and policy formation.
John joined Kroll after a distinguished 27-year career with the U.S. Justice Department, Drug Enforcement Administration (DEA). John had most recently served as Special Agent in Charge of the New England Field Division as a Senior Executive Service member. In his time with the DEA, he developed and led numerous initiatives focusing on disrupting and dismantling transnational organized crime syndicates, with an emphasis on their money laundering and other finance-related activities.
Prior to his most recent role, John had served as the Chief of Global Financial Operations for DEA, where he was responsible for directing, overseeing, and augmenting all of DEA’s financial objectives and strategies as they related to criminal investigations of high-level organizations and their members operating throughout the world. In this capacity, John also was in charge of administering all anti-money laundering and threat finance-related training to the private and regulatory sector as well as to members of the international financial and law enforcement community. As a result, John has successfully built relationships with industry leaders and international partners throughout the world. Additionally in this position, John was responsible for representing DEA within the interagency community as it related to the coordination and implementation of U.S. government sanctions, specifically OFAC and other U.S. Treasury measures targeting global drug trafficking organizations, and the development of national and international anti-money laundering strategies and policies.